BridgeBio Oncology Therapeutics (BBOT) Cash from Operations (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Cash from Operations of 35917000.0 for Q1 2026, up 14.96% sequentially from 42234000.0 in Q4 2025, and down 83.26% YoY from 214549613.84 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Cash from Operations (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Cash from Operations for 3 years, with the latest figure at 35917000.0 in Q1 2026.
- Quarterly Cash from Operations fell 83.26% year-over-year to 35917000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 130212000.0 (down 75.94% YoY) and the FY2025 annual result came in at 113894000.0, down 106.98% from the prior year.
- Cash from Operations climbed to 35917000.0 in Q1 2026 per BBOT's latest filing, from 42234000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 18565454.0 in Q2 2025 and troughed at 70626454.0 in Q3 2025.
- A 3-year average of 22759777.78 and a median of 19599000.0 in 2025 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 63901.0% in 2025, down 3071.36% in 2025.
- Over 3 years, Cash from Operations stood at 15035000.0 in 2024, then tumbled by 180.9% to 42234000.0 in 2025, then climbed by 14.96% to 35917000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 35917000.0, 42234000.0, and 70626454.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -44.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.36 Mn |
| Jun 30, 2026 | -44.36 Mn |
| Mar 31, 2026 | -35.92 Mn |
| Mar 31, 2026 | -35.92 Mn |
| Dec 31, 2025 | -42.23 Mn |
| Dec 31, 2025 | -42.23 Mn |
| Sep 30, 2025 | -70.63 Mn |
| Sep 30, 2025 | -70.63 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Mar 31, 2025 | -19.60 Mn |
| Mar 31, 2025 | -19.60 Mn |
| Dec 31, 2024 | -15.04 Mn |
| Dec 31, 2024 | -15.04 Mn |
| Sep 30, 2024 | -39.34 Mn |
| Sep 30, 2024 | -39.34 Mn |
| Jun 30, 2024 | -29,099.00 |
| Jun 30, 2024 | -29,099.00 |
| Mar 31, 2024 | -617,999.00 |
| Mar 31, 2024 | -617,999.00 |